Avalo Therapeutics Inc
(AVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -47,857 | -34,398 | -21,117 | -16,073 | -17,694 |
| Depreciation Amortization | 1,305 | 879 | 453 | 5,440 | 4,823 |
| Income taxes - deferred | 29 | -424 | 21 | 17 | 29 |
| Accounts receivable | -172 | -532 | -696 | 1,658 | -1,798 |
| Accounts payable and accrued liabilities | -548 | 83 | 251 | 1,019 | -620 |
| Other Working Capital | -3,576 | -2,839 | -2,926 | -2,023 | -5,545 |
| Other Operating Activity | 24,655 | 22,937 | 18,275 | -9,173 | 3,351 |
| Operating Cash Flow | $-26,164 | $-14,294 | $-5,739 | $-19,134 | $-17,454 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -63 | N/A | N/A | -262 | -262 |
| Sale Of Investment | 12,837 | 12,837 | N/A | N/A | N/A |
| Other Investing Activity | -1,251 | -1,251 | -1,251 | -181 | 0 |
| Investing Cash Flow | $11,523 | $11,586 | $-1,251 | $-443 | $-262 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -256 | -73 |
| Common Stock Issued | 44,678 | 44,677 | 5,210 | 10,023 | 13,099 |
| Other Financing Activity | -94 | -94 | 3,888 | 2,793 | -602 |
| Financing Cash Flow | $44,584 | $44,583 | $9,098 | $12,560 | $12,424 |
| Beginning Cash Position | 3,729 | 3,729 | 3,729 | 10,747 | 10,747 |
| End Cash Position | 33,672 | 45,604 | 5,837 | 3,729 | 5,455 |
| Net Cash Flow | $29,943 | $41,875 | $2,108 | $-7,018 | $-5,292 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,164 | -14,294 | -5,739 | -19,134 | -17,454 |
| Capital Expenditure | -63 | N/A | N/A | -262 | -262 |
| Free Cash Flow | -26,227 | -14,294 | -5,739 | -19,396 | -17,716 |